$IMNM News

Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors

Immunome Stock Up 32% in a Month: Here's What You Should Know

Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome's New Drug Application For Desmoid Tumors Treatment Accepted By FDA, April 28, 2027 Assigned As Prescription Drug User Fee Act Target Action Date

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

Immunome Does First Participant In Its Phase 1 IM-1617 Study To Treat Solid Tumors

Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis

Immunome (IMNM) Is Down 12.7% After Phase 3 Varegacestat Data And FDA NDA Filing - Has The Bull Case Changed?

Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting

Truist Securities Maintains Buy on Immunome, Raises Price Target to $37

Barclays Initiates Coverage On Immunome with Overweight Rating, Announces Price Target of $36

What Offers Immunome (IMNM) a Compelling Investment Opportunity?

HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target

Immunome Q1 EPS $(0.48) Beats $(0.57) Estimate

Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors